Frank H. Laukien

Frank H. Laukien (born 1960 in Stuttgart, Germany) is a German-American scientist and entrepreneur, the president and CEO of scientific instrument and life-science tools company Bruker Corporation since 2008.

Born and raised in Germany, where he finished his Abitur in 1979, and served as a paratrooper in the Bundeswehr, before he came to the US to study physics at MIT in 1980. He graduated with a B.Sc. in physics in 1984, and then continued with graduate work at the Harvard University Graduate School of Arts & Sciences, where he received a Ph.D. in chemical physics in 1988 under Professor William Klemperer.

Dr. Frank Laukien joined Bruker in the US in 1988, focusing on the commercial development of the US and Japanese markets, and on R&D in life-science mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. He and his teams contributed market-changing, disruptive innovations which have included actively-shielded NMR magnets, novel NMR CryoProbes, the novel MALDI Biotyper platform for rapid, universal identification in microbiology, ultra-high field NMR magnet technology for structural biology, and most recently trapped ion mobility spectrometry (TIMS) for 4D proteomics.

Dr. Laukien is an inventor in mass spectrometry, NMR and superconducting magnet technology with numerous patents. His present focus is on proteomics and metabolomics, structural biology, microbiology and infectious disease diagnostics, as well as superconducting materials and magnets.

Frank Laukien also is a scientific author with various publications in applied physics and chemical physics, and he has written a book 'Evolution 4.0' on actively accelerated biological evolution.

Early life

Frank Laukien is the son of physics Professor Günther Laukien, the co-founder of Bruker Physik AG, which was a 1960 spin-off from the Technical University of Karlsruhe, Germany. His mother Dr. Rose Laukien was a German high-school (Gymnasium) teacher in German literature, English and History.

After his father Guenther passed away in April 1997, Dr. Frank Laukien established the 'Guenther R. Laukien Prize for Recent Innovations in Magnetic Resonance', which has been awarded annually by the Experimental NMR Conference (ENC), initially under prize committee chair Professor Richard Ernst (ETH), and today under committee chair Professor Robert Griffin (MIT).

As part of his academic interests, in the 1990s Dr. Laukien at various times was a lecturer in NMR and mass spectrometry at the University of Bremen, Germany, and a part-time professor at the Institute of Mass Spectrometry of the University of Amsterdam, NL. 

Dr. Laukien has previously served on the Dean’s Advisory Committee of the School of Science of MIT, and on the Board of the Analytical, Life Science & Diagnostics Association (ALDA), including one year as chairman. In 2017, he has been elected a senator of acatech, the German natural science and engineering academy.


Frank Laukien has been the CEO of Bruker Corporation owns approximately 25% of Bruker, while his brother Joerg Laukien and other Laukien family members own another estimated 11-12% of Bruker Corporation.

Dr. Laukien took the life-science mass spectrometry company Bruker Daltonics public on the NASDAQ in August 2000, and later as he was instrumental in the IPO of analytical X-ray systems company Bruker AXS in late 2001. In 2008, he led the merger of all Bruker entities into one publicly traded company Bruker Corporation (Nasdaq: BRKR), which via organic growth and numerous smaller acquisitions is expected to have about $2 billion in revenue in 2019, with over 6,500 employees worldwide.

Frank Laukien

Frank H. Laukien
Febr. 4, 1960
Stuttart, Germany

ResidenceBoston, MA
EducationPh.D. in Chemical Physics
Alma materMIT and Harward University
OccupationChairman, President and CEO, Bruker
Home townStuttgart, Germany
Net worth~$6 million in net assets, plus iliquid BRKR stock
Parents(s)Professor Gunther Laukien & Dr. Rose Laukien